[Evaluation of acquired data on long-term risk of hypolipidemic treatments]

source extracted confidence: high 2026-04-09
#clofibrate #digestive-system-neoplasms #drug-tolerance #humans #hypolipidemic-agents

[Evaluation of acquired data on long-term risk of hypolipidemic treatments]

Childs et al., 1992 | Arch Mal Coeur Vaiss | Meta Analysis

Citation

Childs M, Girardot G. [Evaluation of acquired data on long-term risk of hypolipidemic treatments]. Arch Mal Coeur Vaiss. 1992-Sep;85 Spec No 2:129-33

Abstract

At present, it is very difficult, if not impossible, to draw reliable conclusions about the long-term risks of lipid lowering therapy. Many so-called "long-term" trials only cover a few years of treatment, comparative studies versus placebo are very rare and the notification of acute events in the context of pharmacovigilance does not provide information about the long-term risk. However, analysis of large scale primary or secondary prevention trials, the Lipid Research Clinics study with cholestyramine, the Helsinki cardiological study with gemfibrozil, the Coronary Drug Project with clofibrate and nicotinic acid, has not shown any significant differences between the treatment and control groups, in particular with regards to the prevalence of malignant disease. These reassuring observations contradict those of the WHO study with clofibrate: a significant increase in the incidence of cancer, especially gastrointestinal, is observed in the treatment group. Therefore, despite the absence of confirmed long-term clinical or biological adverse effects of lipid lowering drugs (apart from the WHO clofibrate study), the physician must remain vigilant, especially as the long-term risks are difficult to assess.

Key Findings

Therefore, despite the absence of confirmed long-term clinical or biological adverse effects of lipid lowering drugs (apart from the WHO clofibrate study), the physician must remain vigilant, especially as the long-term risks are difficult to assess.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population See abstract
Sample Size See abstract
Age Range See abstract
Condition See abstract

MeSH Terms

  • Clofibrate
  • Digestive System Neoplasms
  • Drug Tolerance
  • Humans
  • Hypolipidemic Agents
  • Long-Term Care
  • Product Surveillance, Postmarketing
  • Risk

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: English Abstract, Journal Article, Meta-Analysis
  • Vertical: niacin

Provenance

  • PMID: 1285692
  • DOI: (not available)
  • PMCID: Not in PMC
  • Verified: 2026-04-09 via PubMed E-utilities API

Source extracted via PubMed E-utilities API on 2026-04-09